The present invention relates to a lozenge composition for improved delivery of cannabinoids to mucosal surfaces comprising; i) a mucosal delivery enhancing component comprising one or more cannabinoids, an agent with hydrophobic interacting properties and one or more solid particles, the agent with hydrophobic interacting properties forming an encapsulation of the one or more cannabinoids and the encapsulation being reversibly associated with the one or more solid particles; and ii) an extragranular component blended with the mucosal delivery enhancing component comprising one or more extragranular sugar alcohols
Claim CLM-00138. 138. A lozenge composition for improved delivery of cannabinoids to mucosal surfaces comprising:
i) a mucosal delivery enhancing component comprising one or more cannabinoids, an agent with hydrophobic interacting properties and one or more solid particles, the agent with hydrophobic interacting properties forming an encapsulation of the one or more cannabinoids, the encapsulation being reversibly associated with the one or more solid particles; and ii) an extragranular component blended with the mucosal delivery enhancing component comprising one or more extragranular sugar alcohols.
Claim CLM-00159. 159. A lozenge composition for improved delivery of cannabinoids to mucosal surfaces comprising:
i) a mucosal delivery enhancing component comprising one or more cannabinoids, an agent with hydrophobic interacting properties and one or more solid particles of microcrystalline cellulose, the agent with hydrophobic interacting properties forming an encapsulation of the one or more cannabinoids, the encapsulation being reversibly associated with the one or more solid particles of microcrystalline cellulose; and ii) an extragranular component blended with the mucosal delivery enhancing component comprising one or more extragranular sugar alcohols.
Claim CLM-00160. 160. A lozenge composition for improved delivery of cannabinoids to mucosal surfaces comprising:
i) a mucosal delivery enhancing component comprising one or more cannabinoids, an agent with hydrophobic interacting properties and one or more solid particles of sugar alcohol, the agent with hydrophobic interacting properties forming an encapsulation of the one or more cannabinoids, the encapsulation being reversibly associated with the one or more solid particles of sugar alcohol; and ii) an extragranular component blended with the mucosal delivery enhancing component comprising one or more extragranular sugar alcohols.
